We rank companies based on fund manager, research analyst and news sentiment
AFMD stock icon

Affimed
AFMD

$5.15
1.58%
 

About: Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Employees: 78

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

80% more call options, than puts

Call options by funds: $1.13K | Put options by funds: $625

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

51% more capital invested

Capital invested by funds: $19M [Q3] → $28.7M (+$9.61M) [Q4]

10% more funds holding

Funds holding: 60 [Q3] → 66 (+6) [Q4]

4.03% more ownership

Funds ownership: 26.68% [Q3] → 30.71% (+4.03%) [Q4]

56% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 25

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
3%
downside
Avg. target
$23
337%
upside
High target
$50
871%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Wells Fargo
Yanan Zhu
385%upside
$25
Overweight
Maintained
1 Apr 2024
Stifel
Bradley Canino
3%downside
$5
Hold
Maintained
1 Apr 2024
HC Wainwright & Co.
Swayampakula Ramakanth
94%upside
$10
Buy
Maintained
1 Apr 2024
HC Wainwright & Co.
Swayampakula Ramakanth
871%upside
$50
Buy
Reiterated
15 Nov 2023

Financial journalist opinion

Based on 5 articles about AFMD published over the past 30 days